tiprankstipranks
Advertisement
Advertisement

DE:41O Stock Latest News

Outlook Therapeutics Announces CFO Transition and Board Change
Company AnnouncementsOutlook Therapeutics Announces CFO Transition and Board Change
2d ago
8K
OTLK
Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed
PremiumThe Fly
Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed
2d ago
CV
OTLK
Outlook Therapeutics Earnings Call: LYTENAVA Faces Test
PremiumCompany Announcements
Outlook Therapeutics Earnings Call: LYTENAVA Faces Test
4d ago
OTLK
Outlook Therapeutics delays quarterly SEC filing
PremiumCompany Announcements
Outlook Therapeutics delays quarterly SEC filing
12d ago
OTLK
Outlook Therapeutics: Buy Rating Reiterated as LYTENAVA Launch Strategy Supports Unchanged $4 Price Target
PremiumRatings
Outlook Therapeutics: Buy Rating Reiterated as LYTENAVA Launch Strategy Supports Unchanged $4 Price Target
12d ago
OTLK
Outlook Therapeutics announces common stock, warrants offering
PremiumThe FlyOutlook Therapeutics announces common stock, warrants offering
12d ago
OTLK
Outlook Therapeutics $100M Spot Secondary re-offered at 99c
Premium
The Fly
Outlook Therapeutics $100M Spot Secondary re-offered at 99c
12d ago
OTLK
Outlook Therapeutics 55.6M share Spot Secondary priced at 99c
Premium
The Fly
Outlook Therapeutics 55.6M share Spot Secondary priced at 99c
12d ago
OTLK
Outlook Therapeutics reports Q3 EPS (15c), consensus (8c)
PremiumThe Fly
Outlook Therapeutics reports Q3 EPS (15c), consensus (8c)
13d ago
OTLK
Morning Movers: Applied Materials slips after quarterly earnings
PremiumThe Fly
Morning Movers: Applied Materials slips after quarterly earnings
13d ago
W
FOX
Outlook Therapeutics Announces $55 Million Equity Offering
PremiumCompany Announcements
Outlook Therapeutics Announces $55 Million Equity Offering
15d ago
8K
OTLK
Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks
PremiumCompany Announcements
Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks
17d ago
8K
OTLK
Is OTLK a Buy, Before Earnings?
PremiumPre-EarningsIs OTLK a Buy, Before Earnings?
17d ago
OTLK
Outlook Therapeutics price target raised to $1.60 from 50c at H.C. Wainwright
Premium
The Fly
Outlook Therapeutics price target raised to $1.60 from 50c at H.C. Wainwright
1M ago
OTLK
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
Premium
The Fly
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
1M ago
OTLK
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
PremiumThe Fly
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
1M ago
OTLK
Outlook Therapeutics Gains FDA Approval for LYTENAVA Launch
PremiumCompany Announcements
Outlook Therapeutics Gains FDA Approval for LYTENAVA Launch
1M ago
8K
OTLK
Outlook Therapeutics Inc trading resumes
PremiumThe Fly
Outlook Therapeutics Inc trading resumes
1M ago
OTLK
Outlook Therapeutics announces FDA approval of Lytenava for wet AMD
PremiumThe Fly
Outlook Therapeutics announces FDA approval of Lytenava for wet AMD
1M ago
OTLK
Outlook jumps 24% to $1.64 after FDA approves wet AMD treatment
PremiumThe FlyOutlook jumps 24% to $1.64 after FDA approves wet AMD treatment
1M ago
OTLK
Outlook Therapeutics Inc trading halted, news pending
Premium
The Fly
Outlook Therapeutics Inc trading halted, news pending
1M ago
OTLK
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval
Premium
Company Announcements
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval
1M ago
8K
OTLK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >